1. Home
  2. ATAT vs GKOS Comparison

ATAT vs GKOS Comparison

Compare ATAT & GKOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Atour Lifestyle Holdings Limited

ATAT

Atour Lifestyle Holdings Limited

HOLD

Current Price

$37.74

Market Cap

5.9B

ML Signal

HOLD

Logo Glaukos Corporation

GKOS

Glaukos Corporation

HOLD

Current Price

$100.67

Market Cap

6.3B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ATAT
GKOS
Founded
2013
1998
Country
China
United States
Employees
N/A
N/A
Industry
Hotels/Resorts
Medical/Dental Instruments
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.9B
6.3B
IPO Year
2022
2015

Fundamental Metrics

Financial Performance
Metric
ATAT
GKOS
Price
$37.74
$100.67
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
5
14
Target Price
$46.16
$127.71
AVG Volume (30 Days)
947.7K
601.6K
Earning Date
11-25-2025
02-17-2026
Dividend Yield
1.17%
N/A
EPS Growth
25.36
N/A
EPS
1.48
N/A
Revenue
$1,276,315,178.00
$469,820,000.00
Revenue This Year
$37.82
$31.33
Revenue Next Year
$23.56
$24.01
P/E Ratio
$26.08
N/A
Revenue Growth
36.24
30.38
52 Week Low
$21.50
$73.16
52 Week High
$43.17
$163.71

Technical Indicators

Market Signals
Indicator
ATAT
GKOS
Relative Strength Index (RSI) 38.54 33.11
Support Level $40.25 $109.07
Resistance Level $42.79 $115.00
Average True Range (ATR) 1.60 3.35
MACD -0.39 -1.71
Stochastic Oscillator 15.32 32.74

Price Performance

Historical Comparison
ATAT
GKOS

About ATAT Atour Lifestyle Holdings Limited

Atour Lifestyle Holdings Ltd is an upper-midscale hotel chain in China. The company derives revenues from franchise and management fees from its manachised hotels and sales of hotel supplies to manachised hotels, Operations of leased hotels, and sales of retail products. The company has one operating segment, which is the Atour Group.

About GKOS Glaukos Corporation

Glaukos Corp is an ophthalmic pharmaceutical and medical technology company focused on developing novel, dropless therapies and commercializing associated products for the treatment of glaucoma, corneal disorders, and retinal diseases. It has commenced commercialization activities for iDose TR, a first-of-its-kind, long-duration, intracameral procedural pharmaceutical implant designed to continuously deliver glaucoma drug therapy inside the eye for extended periods of time. The company also offer commercially a proprietary bio-activated pharmaceutical therapy for the treatment of a rare corneal disorder, keratoconus. It has three primary commercialized micro-scale surgical device products designed to treat glaucoma: the iStent, the iStent inject W, and the iStent infinite.

Share on Social Networks: